Form 4: Eli Lilly Director Acquires Shares Through Deferral Plan

Director Juan R. Luciano acquired 16 shares of Eli Lilly common stock at $906.13 per share through a deferral plan.

Summary

• Director Juan R. Luciano acquired 16 shares of Eli Lilly common stock on October 21, 2024.
• The shares were acquired at a price of $906.13 per share.
• These shares were acquired through the Lilly Directors' Deferral Plan.
• The shares will be settled in common stock following the director's separation from service.
• The transaction increased the director's total holdings to 15,825 shares.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally viewed neutrally to slightly positive as it aligns director interests with shareholders.

Positives

• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.

Future Outlook

The acquired shares will be settled in common stock following the director's separation from service.

Industry Context

This is a routine filing related to director compensation and is common practice for publicly traded companies.

Comparison to Industry Standards

• Director share acquisitions through deferral plans are a common practice among large publicly traded companies, such as those in the pharmaceutical sector like Pfizer and Merck.
• These plans are often used to align the interests of directors with those of shareholders, and the specific terms of the deferral plan are typical for executive compensation packages.

Stakeholder Impact

• The share acquisition has a minor positive impact on shareholders as it indicates director confidence in the company.

Key Dates

Keywords

Eli Lilly, Director, Share Acquisition, Deferral Plan, Stock Units, Form 4, Insider Trading